Syngene Q1 profit up 59% to Rs 87 crore

BENGALURU: Syngene International , a subsidairy of Biocon , reported a 59 per cent year-on-year increase in profit after tax to Rs 87 crore in the first quarter ended June 2025, aided by revenue growth and a tax benefit from the transfer of gratuity funds to an employee trust. Revenue from operations rose 11 per cent to Rs 875 crore during the period.

Ebitda grew 19 per cent year-on-year to Rs 224 crore, with margins improving to 25 per cent from 23 per cent a year earlier. CEO Peter Bains said the growth was led by the conversion of pilot programs into long-term contracts in the Research Services division . The company also progressed operations at its Biologics Unit III facility in Bengaluru and prepared for the launch of its Bayview site in the US later this year. It commissioned a new peptide laboratory during the quarter.

The company said it underwent over 20 client and regulatory audits in Q1, including a USFDA GCP inspection of its Human Pharmacology Unit with no observations. Its Biologics facility received an Establishment Inspection Report with a Voluntary Action Indicated outcome.

CFO Deepak Jain said operating Ebitda margins held around 24 per cent, supported by revenue growth and cost optimisation. Syngene said it remains on track to meet its full-year guidance.